Monographie - Trastuzumab

Ostatnia aktualizacja :
19/11/2024

Trastuzumab

Nazwa handlowa

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Herceptin	Arabia Saudyjska, Argentyna, Australia, Austria, Belgia, Brazylia, Chile, Dania, Egipt, Ekwador, Finlandia, Francja , Grecja, Hiszpania, Holandia, Iran, Irlandia, Islandia, Japonia, Kanada, KolumbiaKolumbia, Luksemburg, Malezja, Maroko, Meksyk, Niemcy, Norwegia, nowa Zelandia, Peru, Polska, Portugalia, Rumunia, Stany Zjednoczone Ameryki, Szwajcaria, Szwecja, Turcja, Węgry, Wielka Brytania, Włochy, Zjednoczone Emiraty Arabskie
Herclon	Peru
Hertraz	Chile
Herzuma	Belgia, Francja , Hiszpania, Niemcy, Stany Zjednoczone Ameryki, Wielka Brytania
Kanjinti	Belgia, Hiszpania, Niemcy, Wielka Brytania
Trastuzumab Baxter	nowa Zelandia
Trazimera	Wielka Brytania

Bibliografia : Trastuzumab

	typ	publikacja
2296	Laboratorium	Témocilline (Negaban®) - Résumé des caractéristiques du produit Eumedica 2017
2975	plakat	Nalenz H, Schoenhammer K, Dietel E, Heynen S.R, Grauschopf U, Mahler H.C. In-Use stability of herceptin for subcutaneous injection with different administration materials. ESCP 2014 2014
3077	Laboratorium	Trastuzumab (Herceptin®) – Summary of Product Characteristics Roche 2019
3113	Książka	Herceptin Compendium Suisse des m?dicaments 2010
3258	Czasopismo	Kaiser J, Krämer I. Physicochemical Stability of Diluted Trastuzumab Infusion Solutions in Polypropylene Infusion Bags. Int J Pharm Compound 2011 ; 15, 6 : 515-520.
3343	plakat	Vieillard V, da Silva R, Astier A, Paul M. Physicochemical stability of diluted trastuzumab solutions stored 6 months at 4°C. ECOP Congress, Budapest, Hungary 2012
3366	Czasopismo	Kwong Glover Z.W, Gennaro L, Yadav S, Demeule B, Wong P.Y, Sreedhara A. Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration. J Pharm Sci 2012 ; DOI 10.1002 / jps.23403
3386	Czasopismo	Paul M, Vieillard V, Da Silva Lemos R, Escalup L, Astier A. Long-term physico-chemical stability of diluted trastuzumab. Int J Pharm 2013 ; 448: 101-104.
3647	Laboratorium	Trastuzumab (Herceptin® 600 mg for subcutaneous injection) - Summary of Product Characteristics Roche 2019
3849	Czasopismo	Pabari R.M, Ryan B, Ahmad W, Ramtoola Z. Physical and structural stability of the monoclonal antibody, trastuzumab (Herceptin®), intravenous solutions. Curr Pharm Biotech 2013 ; 14, 2: 220-225.
4163	Czasopismo	Nalenz H, K?pf E, Dietel E. Prolonged In-Use Stability of Reconstituted Herceptin in Commercial Intravenous Bags. Int J Pharm Compound 2018 22;5:417-423
4191	Czasopismo	Vieillard V, Astier A, Paul M. Extended stability of a biosimilar of trastuzumab (CT-P6) after reconstitution in vials, dilution in polyolefin bags and storage at varioustemperatures. GaBI Journal 2018
4194	Czasopismo	Kim S.J, Lee J.W, Kang H.Y, Kim S.Y, Shin Y.K, Kim K.W, Oh J.S, Lim K.J, Kim J.Y. In-Use Physichochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion. Bio Drugs 2018 32;619-625
4271	Czasopismo	Yun J, Kim J, Chung J, Hwang S-J, Park S-J. Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties Adv Ther 2019
4396	Czasopismo	Lueras A, Polozova A, Asbury D, Hippenmeyer J, Litowski J, Goss M, Breslin P, Crampton S. Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentrations and stress conditions. GaBI Journal 2020 ; 9, 1:
4477	Czasopismo	Crampton S, Polozoxa A, Asbury D, Lueras A, Breslin P, Hippenmeyer J, Litkowski J,,Goss M. Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentration and stress conditions. GaBI Journal 2020 ; 9, 1: 5-13.
4493	Czasopismo	Le Guyader G, Vieillard V, Paul M. Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion. J Oncol Pharm Practice 2020
4649	Czasopismo	Davies L, Milligan K, Corris M, Clarke I, Dwyer P, Lee S-E, Teraoka J, Crouse-Zeineddini J, Hippenmeyer J. Extended stability of the trastuzumab biosimilar ABP 980 (KANJINTI™) in polyolefin bags and elastomeric devices. GaBI Journal 2021 ; 10, 4
4754	Czasopismo	Weiser S, Burns C, Zartler E Physicochemical stability of PF-05280014 (trastuzumab-qyyp; TrazimeraTM), a trastuzumab biosimilar, under extended in-use conditions. J Oncol Pharm Practice 2023 ;29,3:

Mentions Légales